Ipsen promotes Aidan Murphy

10 January 2018
ipsen-logo-big

French drugmaker Ipsen (Euronext: IPN) today announced the promotion of Dr Aidan Murphy as executive vice president, technical operations, effectiveJanuary 1, 2018.

Dr Murphy now reports directly to David Meek, chief executive of Ipsen, and serves on the executive leadership team.

Dr Murphy has more than 25 years experience in the pharmaceutical and biotechnology industry, and since joining Ipsen in 2007 has held a number of manufacturing leadership roles in many countries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical